Design Therapeutics (DSGN) EBITDA

Price: $3.88
Market Cap: $220.24M
Avg Volume: 146.94K
Country: US
Industry: Biotechnology
Sector: Healthcare
Beta: 1.824
52W Range: $2.6-7.77
Website: Design Therapeutics

What is Design Therapeutics's EBITDA?

  • Design Therapeutics's annual EBITDA is $-62.38M.
  • Design Therapeutics's quarterly EBITDA is $-16.55M.

What is EBITDA?

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a measure of a company's overall financial performance and is used as an alternative to net income in some circumstances.

How is EBITDA calculated?

EBITDA is calculated using the following formula:

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Related Metrics

Other important metrics to assess Design Therapeutics's financial health include:

  • EBITDA Ratio - measures the company's EBITDA as a percentage of its revenue:
    • Annual: -
    • Quarterly: -
  • Growth EBITDA - measures the annual growth rate of the company's EBITDA:
    • Annual: 5.94%
    • Quarterly: -2.81%
  • Growth EBITDA Ratio - measures the annual growth rate of the company's EBITDA ratio:
    • Annual: 0.00%
    • Quarterly: 0.00%

These metrics provide insights into Design Therapeutics's financial health and its ability to meet short-term obligations. Comparing these ratios with industry benchmarks can offer a deeper understanding of the company's performance.

Annual EBITDA

$-62.38M

Quarterly EBITDA

$-16.55M

Design Therapeutics Historical EBITDA
Historical EBITDA Ratio (Annual)
Historical EBITDA Ratio (Quarterly)

Design Therapeutics Historical EBITDA Metrics

The table below shows various financial metrics for each year, with the latest data available for the last fiscal year 2024.

Year EBITDA Growth EBITDA EBITDA Ratio Growth EBITDA Ratio
2024 $-62.38M 5.94% - 0.00%
2023 $-66.33M -5.54% - 0.00%
2022 $-62.84M -76.02% - 0.00%
2021 $-35.70M -328.85% - 0.00%
2020 $-8.32M -5889.21% -3683628.32% -22001.77%
2019 $-139.00K 0.00% -16666.67% 0.00%

Related Metrics

Explore detailed financial metrics and analysis for DSGN.